Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 11/20 | 0.74 |
| ▸ | CTSS | P25774 | 3/20 | 0.55 |
| ▸ | CCR1 | P32246 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | CBX4 | O00257 | 1/20 | 0.37 |
| ▸ | CBX6 | O95503 | 1/20 | 0.37 |
| ▸ | CBX7 | O95931 | 1/20 | 0.37 |
| ▸ | CBX2 | Q14781 | 1/20 | 0.37 |
| ▸ | CDYL2 | Q8N8U2 | 1/20 | 0.37 |
| ▸ | CBX8 | Q9HC52 | 1/20 | 0.37 |
| ▸ | CTSV | O60911 | 2/20 | 0.36 |
| ▸ | CTSL | P07711 | 2/20 | 0.36 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.36 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4043760 | 0.93 | CTSK (0.71) | CTSKCTSSCCR1TSHRCBX4 | |
| SCHEMBL4039251 | 0.90 | CTSK (0.64) | CTSKCTSSCCR1POLBCTSV | |
| SCHEMBL4047221 | 0.90 | CTSK (0.77) | CTSKCTSSCCR1POLBCTSV | |
| SCHEMBL5941683 | 0.90 | CTSK (0.77) | CTSKCTSSCCR1POLBCTSV | |
| SCHEMBL5941685 | 0.90 | CTSK (0.77) | CTSKCTSSCCR1POLBCTSV | |
| SCHEMBL4044187 | 0.89 | CTSK (0.62) | CTSKCTSSCCR1CTSVCTSL | |
| SCHEMBL5941348 | 0.89 | CTSK (0.75) | CTSKCTSSCCR1CTSVCTSL | |
| SCHEMBL13909147 | 0.89 | CTSK (0.75) | CTSKCTSSCCR1CTSVCTSL | |
| SCHEMBL4041864 | 0.89 | CTSK (0.75) | CTSKCTSSCCR1CTSVCTSL | |
| SCHEMBL4217658 | 0.89 | CTSK (0.75) | CTSKCTSSCCR1CTSVCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1546150-B1 | PYRROLE DERIVATIVES AS INHIBITORS OF CYTEINE PROTEASES | AMURA THERAPEUTICS LTD (GB) | 2009-03-04 | — | — | EP | claimed |
| US-20060100431-A1 | Biologically active compounds | AMURA THERAPEUTICS LIMITED (GB) | 2006-05-11 | — | — | US | claimed |
| EP-1546150-A1 | BIOLOGICALLY ACTIVE COMPOUNDS | Amura Therapeutics Limited (GB) | 2005-06-29 | — | — | EP | claimed |
| WO-2004007501-A1 | BIOLOGICALLY ACTIVE COMPOUNDS | AMURA THERAPEUTICS LIMITED (GB) | 2004-01-22 | — | — | WO | claimed |
| EP-2056799-A2 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING GLAUCOMA OR PROGRESSION THEREOF | Bausch & Lomb Incorporated (US) | 2009-05-13 | — | — | EP | disclosed |
| EP-2051710-A2 | COMPOSITIONS AND METHODS FOR TREATING, REDUCING, AMELIORATING, OR ALLEVIATING POSTERIOR-SEGMENT OPHTHALMIC DISEASES | Bausch & Lomb Incorporated (US) | 2009-04-29 | — | — | EP | disclosed |
| EP-1546150-B1 | PYRROLE DERIVATIVES AS INHIBITORS OF CYTEINE PROTEASES | AMURA THERAPEUTICS LTD (GB) | 2009-03-04 | — | — | EP | disclosed |
| WO-2008027796-A2 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING GLAUCOMA OR PROGRESSION THEREOF | BAUSCH & LOMB INCORPORATED (US) | 2008-03-06 | — | — | WO | disclosed |
| WO-2008021729-A2 | COMPOSITIONS AND METHODS FOR TREATING, REDUCING, AMELIORATING, OR ALLEVIATING POSTERIOR-SEGMENT OPHTHALMIC DISEASES | BAUSCH & LOMB INCORPORATED (US) | 2008-02-21 | — | — | WO | disclosed |
| US-20060100431-A1 | Biologically active compounds | AMURA THERAPEUTICS LIMITED (GB) | 2006-05-11 | — | — | US | disclosed |
| EP-1546150-A1 | BIOLOGICALLY ACTIVE COMPOUNDS | Amura Therapeutics Limited (GB) | 2005-06-29 | — | — | EP | disclosed |
| WO-2004007501-A1 | BIOLOGICALLY ACTIVE COMPOUNDS | AMURA THERAPEUTICS LIMITED (GB) | 2004-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100431-A1 | Biologically active compounds | SOST, CTSK, CTSS | CTSK 2/4885CTSS 3/4885CCR1 100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.